This list is based on the watchlists of people on Stock Events who follow 37Z.F. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
FAQ
What is Target Healthcare REIT stock price today?▼
The current price of 37Z.F is €1.16 EUR — it has increased by +0.87% in the past 24 hours. Watch Target Healthcare REIT stock price performance more closely on the chart.
What is Target Healthcare REIT stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Target Healthcare REIT stocks are traded under the ticker 37Z.F.
What is Target Healthcare REIT revenue for the last year?▼
Target Healthcare REIT revenue for the last year amounts to 0 EUR.
What is Target Healthcare REIT net income for the last year?▼
37Z.F net income for the last year is -106.94M EUR.
Does Target Healthcare REIT pay dividends?▼
Yes, 37Z.F dividends are paid quarterly. The last dividend per share was 0.02 EUR. As of today, Dividend Yield (FWD)% is 5.97%.
How many employees does Target Healthcare REIT have?▼
As of May 26, 2026, the company has 167 employees.
In which sector is Target Healthcare REIT located?▼
Target Healthcare REIT operates in the Health & Wellness sector.
When did Target Healthcare REIT complete a stock split?▼
Target Healthcare REIT has not had any recent stock splits.